B

휴젤

145020KOSDAQ기초 의약물질 제조업

63.8 / 100

Reference Date: 2026-06-10

Financial Score28.5 / 40
News Sentiment21.3 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Declined 6.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hujeel develops and manufactures biopharmaceuticals based on Clostridium botulinum type A toxin, and directly handles sales after merging with its subsidiary, Hujel Pharma, in 2018. Its major subsidiary, Acros, focuses on HA filler development and production. Both botulinum toxin and HA fillers have broad applications in medical and cosmetic fields.

Number of Employees

629people

Average Salary

64.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
18.53Industry Average 27.716.5Point

Lower than industry avg (good)

PBR
3.04Industry Average 1.741.0Point

1.7x industry avg (risky)

ROE
16.14Industry Average -6.033.5Point

Well below industry avg

Debt Ratio
0.37Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20259.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲15.3% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲31.0% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 15.3% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 6Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 242,000Won52-week high 388,00052-week low 214,000
1-month return2.0Point

1m -6.74% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-06-01
  • Neutral분기보고서 (2026.03)2026-05-15
  • Neutral주식등의대량보유상황보고서(약식)2026-05-13